Effects Of High-Dose Hormone Therapy In Patients With Thyroid-Associated Orbitopathy And Its Effect On Visual Acuity And Ocular Surface

Objective: To explore the effects of high-dose hormone therapy (HHT) in patients with thyroid-associated orbitopathy and its effect on visual acuity and ocular surface. Methods: A total of 68 patients with thyroid-associated orbitopathy were randomized into a control group (n=34 cases and 47 affected eyes) treated with prednisone acetate tablets and an observation group (n=34 cases and 51 affected eyes) treated with HHT. After 6 months of medical intervention, the clinical treatment efficacy, visual acuity, ocular surface changes, life of quality and drug safety were compared between the two groups. Results: The degree of eyeball protrusion and palpebral fissure length (PFL) in the observation group were higher than those of the control group 6 months after treatment (P<0.05). The Clinical Activity Score Scale (CAS) scores of the two groups were lower at 1, 3 and 6 months after treatment than before treatment (P<0.05). The CAS score of the observation group at 1, 3 and 6 months after treatment was lower in observation group than control group (P<0.05). The visual acuity of the observation group at 1, 3 and 6 months was better than that of the control group (P<0.05). The observation group showed higher levels of TMH, BUT, and Slt after 6 months of treatment than the control group (P<0.05). The quality of life of the observation group was higher than that of the control group at 6 months after treatment (P<0.05). No significant difference was found in the incidence of adverse reactions between the two groups during the treatment (P>0.05). Conclusion: HHT in patients with thyroid-associated orbitopathy exhibited higher short-term treatment efficacy and improved visual acuity, ocular surface environment as well as quality of life, without increasing the incidence of adverse reactions.